QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

NCT06716970 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

810

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: QR12000 75mg
DRUG: QR12000 75mg placebo
DRUG: QR12000 150mg
DRUG: QR12000 150mg placebo
DRUG: Sacubitril/valsartan 200mg
DRUG: Sacubitril/valsartan 200mg placebo

Sponsor

Wuhan Createrna Science and Technology Co., Ltd